Increased concentrations of plasma growth arrest-specific 6 and its soluble tyrosine kinase receptor sAxl in Taiwanese women with pelvic inflammatory disease

Shiuan Chih Chen, Jiunn Liang Ko, Shun Fa Yang, Min Yu Tsai, Hsiu Ting Tsai, Chih Hsin Tang, Po Hui Wang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Backgrounds: To investigate the concentrations of plasma growth arrest-specific protein 6 (Gas6) and its soluble tyrosine kinase receptor sAxl in women with pelvic inflammatory disease (PID) and their association with clinical outcomes of PID. Methods: Blood specimens were consecutively collected from the 64 patients with PID before and after treatment and 70 healthy women in university hospital. Concentrations of plasma Gas6 and sAxl were detected using enzyme-linked immunosorbent assay. Results: The concentration of plasma Gas6 and sAxl was significantly increased in the patients with PID compared to the healthy controls, and then reduced significantly after treatment. Gas6 was significantly correlated with sAxl. When we selected 7.5 and 15.2. ng/ml as the cutoff concentration of plasma Gas6 and sAxl to detect PID respectively, the sensitivities of Gas6 and sAxl were 76.6% and 75.0%. When Gas6 and sAxl were combined, the sensitivity rose to 92.2%. They were not related to the incidences of tuboovarian abscesses and surgery, which were, however, significantly associated with length of hospital stay. Conclusions: Novel application of Gas6 or sAxl in combination had a high sensitivity to detect PID and is important in order to prevent severe sequelae.

Original languageEnglish
Pages (from-to)85-90
Number of pages6
JournalClinica Chimica Acta
Volume426
DOIs
Publication statusPublished - Nov 15 2013
Externally publishedYes

Fingerprint

Pelvic Inflammatory Disease
Receptor Protein-Tyrosine Kinases
Plasmas
Growth
Length of Stay
Immunosorbents
growth arrest-specific protein 6
Abscess
Surgery
Assays
Blood
Enzyme-Linked Immunosorbent Assay
Association reactions
Incidence
Enzymes
Therapeutics

Keywords

  • Growth arrest-specific protein 6
  • Pelvic inflammatory disease
  • SAxl
  • Sensitivity

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Increased concentrations of plasma growth arrest-specific 6 and its soluble tyrosine kinase receptor sAxl in Taiwanese women with pelvic inflammatory disease. / Chen, Shiuan Chih; Ko, Jiunn Liang; Yang, Shun Fa; Tsai, Min Yu; Tsai, Hsiu Ting; Tang, Chih Hsin; Wang, Po Hui.

In: Clinica Chimica Acta, Vol. 426, 15.11.2013, p. 85-90.

Research output: Contribution to journalArticle

Chen, Shiuan Chih ; Ko, Jiunn Liang ; Yang, Shun Fa ; Tsai, Min Yu ; Tsai, Hsiu Ting ; Tang, Chih Hsin ; Wang, Po Hui. / Increased concentrations of plasma growth arrest-specific 6 and its soluble tyrosine kinase receptor sAxl in Taiwanese women with pelvic inflammatory disease. In: Clinica Chimica Acta. 2013 ; Vol. 426. pp. 85-90.
@article{d69a3135b63f48bd831ed31fdd9ade2a,
title = "Increased concentrations of plasma growth arrest-specific 6 and its soluble tyrosine kinase receptor sAxl in Taiwanese women with pelvic inflammatory disease",
abstract = "Backgrounds: To investigate the concentrations of plasma growth arrest-specific protein 6 (Gas6) and its soluble tyrosine kinase receptor sAxl in women with pelvic inflammatory disease (PID) and their association with clinical outcomes of PID. Methods: Blood specimens were consecutively collected from the 64 patients with PID before and after treatment and 70 healthy women in university hospital. Concentrations of plasma Gas6 and sAxl were detected using enzyme-linked immunosorbent assay. Results: The concentration of plasma Gas6 and sAxl was significantly increased in the patients with PID compared to the healthy controls, and then reduced significantly after treatment. Gas6 was significantly correlated with sAxl. When we selected 7.5 and 15.2. ng/ml as the cutoff concentration of plasma Gas6 and sAxl to detect PID respectively, the sensitivities of Gas6 and sAxl were 76.6{\%} and 75.0{\%}. When Gas6 and sAxl were combined, the sensitivity rose to 92.2{\%}. They were not related to the incidences of tuboovarian abscesses and surgery, which were, however, significantly associated with length of hospital stay. Conclusions: Novel application of Gas6 or sAxl in combination had a high sensitivity to detect PID and is important in order to prevent severe sequelae.",
keywords = "Growth arrest-specific protein 6, Pelvic inflammatory disease, SAxl, Sensitivity",
author = "Chen, {Shiuan Chih} and Ko, {Jiunn Liang} and Yang, {Shun Fa} and Tsai, {Min Yu} and Tsai, {Hsiu Ting} and Tang, {Chih Hsin} and Wang, {Po Hui}",
year = "2013",
month = "11",
day = "15",
doi = "10.1016/j.cca.2013.09.006",
language = "English",
volume = "426",
pages = "85--90",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - Increased concentrations of plasma growth arrest-specific 6 and its soluble tyrosine kinase receptor sAxl in Taiwanese women with pelvic inflammatory disease

AU - Chen, Shiuan Chih

AU - Ko, Jiunn Liang

AU - Yang, Shun Fa

AU - Tsai, Min Yu

AU - Tsai, Hsiu Ting

AU - Tang, Chih Hsin

AU - Wang, Po Hui

PY - 2013/11/15

Y1 - 2013/11/15

N2 - Backgrounds: To investigate the concentrations of plasma growth arrest-specific protein 6 (Gas6) and its soluble tyrosine kinase receptor sAxl in women with pelvic inflammatory disease (PID) and their association with clinical outcomes of PID. Methods: Blood specimens were consecutively collected from the 64 patients with PID before and after treatment and 70 healthy women in university hospital. Concentrations of plasma Gas6 and sAxl were detected using enzyme-linked immunosorbent assay. Results: The concentration of plasma Gas6 and sAxl was significantly increased in the patients with PID compared to the healthy controls, and then reduced significantly after treatment. Gas6 was significantly correlated with sAxl. When we selected 7.5 and 15.2. ng/ml as the cutoff concentration of plasma Gas6 and sAxl to detect PID respectively, the sensitivities of Gas6 and sAxl were 76.6% and 75.0%. When Gas6 and sAxl were combined, the sensitivity rose to 92.2%. They were not related to the incidences of tuboovarian abscesses and surgery, which were, however, significantly associated with length of hospital stay. Conclusions: Novel application of Gas6 or sAxl in combination had a high sensitivity to detect PID and is important in order to prevent severe sequelae.

AB - Backgrounds: To investigate the concentrations of plasma growth arrest-specific protein 6 (Gas6) and its soluble tyrosine kinase receptor sAxl in women with pelvic inflammatory disease (PID) and their association with clinical outcomes of PID. Methods: Blood specimens were consecutively collected from the 64 patients with PID before and after treatment and 70 healthy women in university hospital. Concentrations of plasma Gas6 and sAxl were detected using enzyme-linked immunosorbent assay. Results: The concentration of plasma Gas6 and sAxl was significantly increased in the patients with PID compared to the healthy controls, and then reduced significantly after treatment. Gas6 was significantly correlated with sAxl. When we selected 7.5 and 15.2. ng/ml as the cutoff concentration of plasma Gas6 and sAxl to detect PID respectively, the sensitivities of Gas6 and sAxl were 76.6% and 75.0%. When Gas6 and sAxl were combined, the sensitivity rose to 92.2%. They were not related to the incidences of tuboovarian abscesses and surgery, which were, however, significantly associated with length of hospital stay. Conclusions: Novel application of Gas6 or sAxl in combination had a high sensitivity to detect PID and is important in order to prevent severe sequelae.

KW - Growth arrest-specific protein 6

KW - Pelvic inflammatory disease

KW - SAxl

KW - Sensitivity

UR - http://www.scopus.com/inward/record.url?scp=84884749393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884749393&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2013.09.006

DO - 10.1016/j.cca.2013.09.006

M3 - Article

VL - 426

SP - 85

EP - 90

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -